Stock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss

Stock Track

May 06

Arcus Biosciences Inc. (RCUS) experienced a significant after-hours plunge of 5.49% following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on key metrics.

The biopharmaceutical company reported a quarterly loss of $1.02 per share, missing the consensus estimate of $0.93 per share. More notably, revenue of $17 million represented a substantial miss against the expected $29.484 million and marked a 39.29% decline compared to the same period last year. The company's net loss widened to $128 million from $112 million a year earlier.

The revenue decline was primarily attributed to lower development services revenue from the company's collaboration with Gilead Sciences. Despite ending the quarter with $876 million in cash and projecting a runway into at least the second half of 2028, the significant earnings and revenue misses prompted a negative market reaction in post-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1186870467"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186870467\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186870467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186870467","market":"us","top_or_hot":-1,"title":"Stock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss","media":"Stock Track","content":"<p>Arcus Biosciences Inc. (RCUS) experienced a significant after-hours plunge of 5.49% following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on key metrics.</p><p>The biopharmaceutical company reported a quarterly loss of $1.02 per share, missing the consensus estimate of $0.93 per share. More notably, revenue of $17 million represented a substantial miss against the expected $29.484 million and marked a 39.29% decline compared to the same period last year. The company's net loss widened to $128 million from $112 million a year earlier.</p><p>The revenue decline was primarily attributed to lower development services revenue from the company's collaboration with Gilead Sciences. Despite ending the quarter with $876 million in cash and projecting a runway into at least the second half of 2028, the significant earnings and revenue misses prompted a negative market reaction in post-market trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 04:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arcus Biosciences Inc. (RCUS) experienced a significant after-hours plunge of 5.49% following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on key metrics.</p><p>The biopharmaceutical company reported a quarterly loss of $1.02 per share, missing the consensus estimate of $0.93 per share. More notably, revenue of $17 million represented a substantial miss against the expected $29.484 million and marked a 39.29% decline compared to the same period last year. The company's net loss widened to $128 million from $112 million a year earlier.</p><p>The revenue decline was primarily attributed to lower development services revenue from the company's collaboration with Gilead Sciences. Despite ending the quarter with $876 million in cash and projecting a runway into at least the second half of 2028, the significant earnings and revenue misses prompted a negative market reaction in post-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCUS","symbol_name":"Arcus Biosciences Inc.","start_time":0,"source_url":"","article_id":"1186870467","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186870467","pubTimestamp":1778014361,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcus Biosciences Inc. (RCUS) experienced a significant after-hours plunge of 5.49% following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCUS":"Arcus Biosciences Inc."},"translate_title":"个股追踪|Arcus Biosciences盘后暴跌5.49%因Q1盈利未达预期令人失望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCUS":1},"content_text":"Arcus Biosciences Inc. (RCUS) experienced a significant after-hours plunge of 5.49% following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on key metrics.The biopharmaceutical company reported a quarterly loss of $1.02 per share, missing the consensus estimate of $0.93 per share. More notably, revenue of $17 million represented a substantial miss against the expected $29.484 million and marked a 39.29% decline compared to the same period last year. The company's net loss widened to $128 million from $112 million a year earlier.The revenue decline was primarily attributed to lower development services revenue from the company's collaboration with Gilead Sciences. Despite ending the quarter with $876 million in cash and projecting a runway into at least the second half of 2028, the significant earnings and revenue misses prompted a negative market reaction in post-market trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}